In Brief: Biocraft Labs
Biocraft Labs: Reports Aug. 3 that FDA has completed recent inspections of dosage-form facilities and quality control labs and has found Biocraft in "substantial compliance" with cGMP regulations. The inspections were a condition of a Justice Department consent decree signed by Biocraft July 28, 1994. FDA now is inspecting Biocraft's R&D labs in connection with new product submissions...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth